These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19181648)

  • 21. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management.
    Scranton RE; Goldstein I; Stecher VJ
    J Sex Med; 2013 Feb; 10(2):551-61. PubMed ID: 23153075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Real-Life Safety and Efficacy of vardenafil (REALISE) study: results in men from Europe and overseas with erectile dysfunction and cardiovascular or metabolic conditions.
    Van Ahlen H; Zumbé J; Stauch K; Hanisch JU
    J Sex Med; 2010 Sep; 7(9):3161-9. PubMed ID: 20646189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease.
    Ganz P
    Am J Cardiol; 2005 Dec; 96(12B):8M-12M. PubMed ID: 16387559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
    Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
    J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior.
    Hedelin H; Ströberg P
    Drugs; 2005; 65(16):2245-51. PubMed ID: 16266193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vardenafil: a review of its use in erectile dysfunction.
    Keating GM; Scott LJ
    Drugs; 2003; 63(23):2673-703. PubMed ID: 14636086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global experiences with vardenafil in men with erectile dysfunction and underlying conditions.
    Eardley I; Lee JC; Guay AT
    Int J Clin Pract; 2008 Oct; 62(10):1594-603. PubMed ID: 18822030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD; Francis SH; Webb DJ
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors.
    Hellstrom WJ
    Int J Clin Pract; 2007 Sep; 61(9):1547-54. PubMed ID: 17655683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic review of the association between erectile dysfunction and cardiovascular disease.
    Gandaglia G; Briganti A; Jackson G; Kloner RA; Montorsi F; Montorsi P; Vlachopoulos C
    Eur Urol; 2014 May; 65(5):968-78. PubMed ID: 24011423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.
    Sussman DO
    J Am Osteopath Assoc; 2004 Mar; 104(3 Suppl 4):S11-5. PubMed ID: 15083994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs.
    Fabbri A; Aversa A
    Int J Androl; 2005 Dec; 28 Suppl 2():69-73. PubMed ID: 16236069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health.
    Kloner RA; Burnett AL; Miner M; Blaha MJ; Ganz P; Goldstein I; Kim NN; Kohler T; Lue T; McVary KT; Mulhall JP; Parish SJ; Sadeghi-Nejad H; Sadovsky R; Sharlip ID; Rosen RC
    J Sex Med; 2024 Jan; 21(2):90-116. PubMed ID: 38148297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient.
    Kloner RA
    Endocrine; 2004; 23(2-3):125-9. PubMed ID: 15146090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA.
    Mulhall JP; Luo X; Zou KH; Stecher V; Galaznik A
    Int J Clin Pract; 2016 Dec; 70(12):1012-1018. PubMed ID: 28032424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence.
    Morales AM; Mirone V; Dean J; Costa P
    Clin Interv Aging; 2009; 4():463-72. PubMed ID: 20054411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelial effects of drugs designed to treat erectile dysfunction.
    Aversa A; Caprio M; Rosano GM; Spera G
    Curr Pharm Des; 2008; 14(35):3768-78. PubMed ID: 19128229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis and treatment of erectile dysfunction for reduction of cardiovascular risk.
    Nehra A; Jackson G; Miner M; Billups KL; Burnett AL; Buvat J; Carson CC; Cunningham GR; Goldstein I; Guay AT; Hackett G; Kloner RA; Kostis J; Montorsi P; Ramsey M; Rosen RC; Sadovsky R; Seftel AD; Vlachopoulos C; Wu FC
    J Urol; 2013 Jun; 189(6):2031-8. PubMed ID: 23313195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.